2016
Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective
Kendall EA, Cohen T, Mitnick CD, Dowdy DW. Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective. International Journal Of Infectious Diseases 2016, 56: 185-189. PMID: 28007660, PMCID: PMC5576040, DOI: 10.1016/j.ijid.2016.12.010.Peer-Reviewed Original ResearchConceptsSecond-line drug susceptibility testingRifampin-resistant tuberculosisDrug susceptibility testingSecond-line drug resistanceDrug resistanceSusceptibility testingHigh-burden settingsSecond-line drugsDrug-resistant tuberculosisEffective regimensTreatment failureTreatment outcomesSmall incremental costEpidemiologic benefitsResistance amplificationPatientsTuberculosisIncremental costMost settingsWidespread implementationSettingRegimensPrevalence
2012
Linking Surveillance with Action against Drug-Resistant Tuberculosis
Cohen T, Manjourides J, Hedt-Gauthier B. Linking Surveillance with Action against Drug-Resistant Tuberculosis. American Journal Of Respiratory And Critical Care Medicine 2012, 186: 399-401. PMID: 22592806, PMCID: PMC3443807, DOI: 10.1164/rccm.201203-0394pp.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisForms of TBDrug-resistant TBManagement of patientsDrug-resistant tuberculosisSecond-line drugsEffective public health responseDrug susceptibility testingPublic health responseQuality-assured treatmentMDRTB treatmentIncident casesHigh burdenProgrammatic dataHealth responseDrug resistanceSusceptibility testingImproved surveillance methodsPopulation subgroupsSurveillance methodsSurveillance activitiesTuberculosisClear roleTreatmentRecent global estimates